VectivBio is a spin out of Therachon, that will focus on conditions caused by well understood molecular alterations that can be targeted with transformational therapeutics.

Our lead product candidate is apraglutide, a next-generation, synthetic GLP-2 analog that has undergone extensive preclinical characterization and optimization as well as early clinical testing. It is being developed as a once-weekly, potential best-in-class therapeutic for the treatment of short bowel syndrome (SBS). Apraglutide is designed to increase the intestine’s ability to absorb fluid and nutrients and minimize the burden of parenteral support, thereby improving patients’ quality of life and their ability to thrive. Apraglutide is currently being investigated in Phase 2 clinical trials.

We look forward to sharing more about VectivBio in the near future.

Management Team

We have assembled a world-class team with deep expertise and an established track record of success in R&D, commercialization and business development for innovative products targeting conditions with major unmet medical need.

Our team brings strong scientific, operational and financial knowledge to the table, along with the passion, entrepreneurial spirit and adaptability necessary to develop potentially life-changing therapeutics for people living with serious unmet medical needs.